Evolent Health, Inc. reaffirmed its revenue guidance for the second quarter and full year 2025 in an SEC filing. The company continues to expect second-quarter 2025 revenue to be in the range of $440 million to $470 million.
For the full year ending December 31, 2025, Evolent Health reiterated its revenue guidance of $2.06 billion to $2.11 billion. This reaffirmation provides clarity on the company's financial expectations for the upcoming periods.
The consistent guidance indicates management's confidence in its operational plans and market position. Investors can use this information to assess the company's projected top-line performance for the remainder of the year.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.